Description

2-Bromo-6Beta,9-Difluoro-11Beta,17,21-Trihydroxypregna-1,4-Diene-3,20-Dione 21-Acetate is a high-purity, synthetic corticosteroid derivative, specifically a halogenated and fluorinated pregnane, serving as a critical advanced pharmaceutical intermediate. Its value lies in its role as a key building block for the synthesis of potent topical anti-inflammatory and anti-pruritic medications. This compound is essential for research and development laboratories and manufacturing facilities within the global pharmaceutical industry, particularly those focused on dermatological and ophthalmic therapeutics.

Application

• Pharmaceutical Intermediate: Primary use as a precursor in the multi-step synthesis of potent topical corticosteroids, such as Halobetasol Propionate and related analogues.
• Active Pharmaceutical Ingredient (API) Development: Serves as a core structural moiety in the research and development of new steroid-based drugs targeting inflammation and immune response.
• Dermatological Drug Synthesis: Critical for manufacturing high-potency creams, ointments, and lotions used to treat severe skin conditions like psoriasis, eczema, and dermatitis.
• Ophthalmic Preparation Research: Used in developing steroid formulations for treating inflammatory eye conditions.
• Biochemical Research: Employed in academic and industrial research to study glucocorticoid receptor activity, steroid metabolism, and structure-activity relationships (SAR).
• Process Chemistry & Scale-Up: Used by process chemists to optimize synthetic routes and scale-up production for commercial manufacturing.

Basic Information

Item	Details
Product Name	2-Bromo-6Beta,9-Difluoro-11Beta,17,21-Trihydroxypregna-1,4-Diene-3,20-Dione 21-Acetate
CAS No.	57781-23-4
Molecular Formula	C23H26BrF2O6
Molecular Weight	525.36 g/mol
Synonyms	21-Acetoxy-2-bromo-6β,9-difluoro-11β,17-dihydroxypregna-1,4-diene-3,20-dione; 2-Bromo-6β,9-difluoro-11β,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate; Halobetasol Propionate Intermediate; 6β,9-Difluoro-11β,17,21-trihydroxy-2-bromopregna-1,4-diene-3,20-dione 21-acetate; U-82207; Bromo-Difluoro Trihydroxy Pregna Diene Dione Acetate; 2-Bromo-6β,9α-difluoro-11β,17α,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate
EINECS	Contact for details

Quality Control

Our 2-Bromo-6Beta,9-Difluoro-11Beta,17,21-Trihydroxypregna-1,4-Diene-3,20-Dione 21-Acetate is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing, including HPLC for purity, identity confirmation by IR and NMR, and residual solvent analysis, to ensure it meets the stringent requirements for pharmaceutical intermediates. Certificates of Analysis (COA) documenting full specifications are provided with every shipment. We support compliance with cGMP, ICH Q7, and relevant pharmacopeial guidelines as required.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated area at a controlled room temperature (15-25°C). Keep the container tightly sealed to protect from moisture. Store away from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (IR)	Conforms to reference spectrum
Identification (HPLC)	Retention time corresponds to reference standard
Purity (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Loss on Drying	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 20 ppm
Residual Solvents (GC)	Complies with ICH Q3C guidelines

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.